PROADAPT-ovary/EWOC-2

Not Applicable

Recruiting

• Conditions: Ovarian Cancer; Surgery
• Interventions: Behavioral: PROADAPT program

• Registration Number: NCT04284969
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

PROADAPT is a standardized geriatric intervention that is currently being co-constructed during an exploratory phase on a multi-professional and multi-disciplinary basis after a systematic analysis of published data (Figure).

It consists in: 1) before surgery: a prehabilitation of the patients including a nutritional, physical and educational preparation; 2) during the hospitalization for surgery: an optimisation of their treatments through a pharmaceutical conciliation, educational interventions, standardization of surgical procedures and enhanced rehabilitation after surgery; 3) bridging and post-discharge interventions for hospital-to-home transition.

This intervention is based on a logic change model, constructed with literature data and validated by an expert group through a DELPHI method : the rehabilitation model.

This intervention was designed to be implemented pragmatically in the centers according local habits and is currently being evaluated in several distinct hospital contexts under the name of "PROADAPT pilot study" in different tumor contexts thanks to a grant from the Regional Health Agency of Rhône-Alpes Auvergne region.

PROADAPT intervention is planned to be evaluated in 4 tumor models inducing complex medico-surgical procedures considered at high risk of geriatric deconditioning. They have the same primary objectives in order to be evaluated into a meta-analysis. Results will be used to test the validity of the rehabilitation model. Therefore, it is a study reaching the goal of the population health intervention research.

The purpose of the PROADAPT-ovary/EWOC-2 study is to evaluate the impact of PROADAPT on patient's post-surgical outcomes in patients ≥ 70 years old with an advanced ovarian cancer (AOC).

Detailed Description

With the conjunction of increased life expectancy and the increasing incidence of cancer with aging, older patient represent an increasing proportion of cancer patients. Increasing age is also associated with increased risk of co-morbidities as well as a decline of functional reserve of multiple organ systems, eventually leading in the context of the disease-and/or the treatment-related stress to functional deconditioning or organ failure.

Surgery or complex medico-surgical procedures can be considered as one proof-of principle of such risks, since major cancer surgery the older population is at higher risk of morbi-mortality and unplanned hospitalization for geriatric events1.

In order to reduce complications after surgery, prehabilitation has often been considered, and 71% of the surgeons would accept a 4 weeks delay before surgery to improve patients' outcomes if shown to be beneficial2. However, the actual level of evidence depends on the interventions: high for pre-operative nutrition3, but low for physical exercise, due to heterogeneous programs with often bad adherence4. In addition, geriatric validated interventions, in order to prevent iatrogenic event, may be added in a multi-interventional model of intervention.

Study Timeline

• Study First Submitted: 2020-02-24
• Study First Submitted QC: 2020-02-24
• Study First Posted: 2020-02-26
• Study Start: 2021-06-03
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-20
• Last Update Posted: 2024-12-27
• Primary Completion: 2025-03-06
• Study Completion: 2027-03-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 292

Inclusion Criteria

• Woman ≥70 year old OR Woman ≥60 years with significant comorbid condition (modified Charlson index≥3) or disability (ADL score<6/6);
• Histologically or cytologically proven FIGO (International Federation of Gynecology and Obstetrics) stage III to IV epithelial ovarian cancer or peritoneal primary or fallopian tube. A cytological proof is accepted if associated with a ratio of CA125/CEA >25 and a radiological pelvic mass.
• Patient oriented towards a complex medical procedure defined by pelvic surgery preceded or not by antineoplastic treatment (neoadjuvant chemotherapy).
• Therapeutic decision validated in a multidisciplinary consultation meeting
• Life expectancy > 3 months.
• Written informed consent obtained.
• Covered by a Health System where applicable.

Read More

Exclusion Criteria

• Any other progressive malignant tumor interfering with the patient's prognosis.
• Patient whose validated therapeutic management does not include cytoreductive surgery.
• Patient unable to be regularly followed up for any reason (geographic, family, social, psychological).
• Patient unable to understand the questionnaires.
• Patient unable to follow and adhere to test procedures for geographic, social or psychological reasons.
• Patient placed under guardianship or curatorship.
• Patient deprived of liberty.
• Concurrent participation in another interventional drug trial.
• Patient already included in this study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention arm : PROADAPT program	PROADAPT program	Patients benefiting from the PROADAPT (interventional arm) program.

Primary Outcome Measures

Name	Time	Method
Superiority of HRQOL on the dimensions	At 3 months	Superiority of HRQOL on the dimensions: Mobility, burden of illness, emotional and physical functioning, fatigue, at 3 months
Superiority for post-treatment complication grade≥3	At 30 days post-treatment	• Superiority for post-treatment complication grade≥3 according the NCI-CTC-v4 (Common Terminology Criteria : CTC) at 30 days

Secondary Outcome Measures

Name	Time	Method
Post-operative morbidity according Clavien-Dindo classification at 30 and 90 days	At 30 and 90 days	Clavien Dindo classification consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V). The introduction of the subclasses a and b allows a contraction of the classification into 5 grades (I, II, III, IV and V) depending on the size of the population observed or the of the focus of a study.; Complications that have the potential for long-lasting disability after patient's discharge (e.g.: paralysis of a voice cord after thyroid surgery) are highlighted in the present classification by a suffix ("d" for disability). This suffix indicates that a follow-up is required to comprehensively evaluate the outcome and related long-term quality of life.
Progression free survival	2 years	Progression-free survival (PFS) is defined as the time from random assignment to disease progression or death from any cause.
Therapeutic strategy (treatment plan completion rate)	2 years	A complete therapeutic strategy consists of a complete cytoreductive surgery (CC0) 6 courses of chemotherapy at least in total, either in neo-adjuvant or in adjuvant setting, with at least 2 courses after surgery.
Overall survival	2 years	Overall survival is defined as the time from randomization to death from any cause

Trial Locations

Locations (11)

CH Métropole Savoie; 🇫🇷 Chambery, France

Centre Georges François Leclerc; 🇫🇷 Dijon, France

Hôpital Croix Rousse; 🇫🇷 Lyon, France

Chu Bordeaux Pellegrin; 🇫🇷 Bordeaux, France

Centre hospitalier Annecy Genevois; 🇫🇷 Pringy, France

CHU de St Etienne - Service gynécologie; 🇫🇷 Saint-Priest-en-Jarez, France

CHU Nord Saint Etienne - Service oncologie médicale; 🇫🇷 Saint-Priest-en-Jarez, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France

Médipôle Hôpital Mutualiste; 🇫🇷 Villeurbanne, France

Villeurbanne Médipole MHP; 🇫🇷 Villeurbanne, France

Service de Gériatrie, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet; 🇫🇷 Pierre-Bénite, France